Nusirt

NuSirt Sciences is a biotechnology company focused on developing products targeting metabolic diseases associated with over-nutrition such as obesity, diabetes, and inflammatory stress. The company has developed a breakthrough technology platform that combines natural compounds with various pharmaceutical agents.

NuSirts first product, NS-0100, uses NuSirts platform technology to combine the natural product leucine with a very low dose of metformin for the treatment of type II diabetes. Although, metformin is the gold standard in the treatment of early-type II diabetes many patients can not tolerate the adverse gastrointestinal side effects metformin can cause in some patients.

The company is currently testing varying doses of NS-0100 in Phase 2 clinical study to find the most efficacious dose of this new combination. If NuSirts clinical trials are successful NS-0100 may offer patients a viable alternative to metformin. NuSirt has filed eleven patent applications (two of which have been issued) and completed four clinical and numerous pre-clinical studies based on the patented technologies.

Nusirt headquartered in United States, North America, operates in the Biotechnology, Clinical Trials, Diabetes sector. The company focuses on Biotechnology and has secured $1.2B in funding across 72 round(s). With a team of 1-10 employees, Nusirt is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Nusirt, raised $600.0K. Discover more about their projects, partnerships, and impact on our platform.